BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19893039)

  • 21. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
    Furusato B; Gao CL; Ravindranath L; Chen Y; Cullen J; McLeod DG; Dobi A; Srivastava S; Petrovics G; Sesterhenn IA
    Mod Pathol; 2008 Feb; 21(2):67-75. PubMed ID: 18065961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
    Chen G; Sircar K; Aprikian A; Potti A; Goltzman D; Rabbani SA
    Cancer; 2006 Jul; 107(2):289-98. PubMed ID: 16752412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue.
    Giangreco AA; Vaishnav A; Wagner D; Finelli A; Fleshner N; Van der Kwast T; Vieth R; Nonn L
    Cancer Prev Res (Phila); 2013 May; 6(5):483-94. PubMed ID: 23503652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
    Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
    J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer.
    Romanuik TL; Wang G; Morozova O; Delaney A; Marra MA; Sadar MD
    BMC Med Genomics; 2010 Sep; 3():43. PubMed ID: 20868494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
    Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
    PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome.
    Callen DF; Ricciardelli C; Butler M; Stapleton A; Stahl J; Kench JG; Horsfall DJ; Tilley WD; Schulz R; Nesland JM; Neilsen PM; Kumar R; Holm R
    Oncol Rep; 2010 Apr; 23(4):1045-52. PubMed ID: 20204290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mRNA and micro-RNA expression analysis in laser-capture microdissected prostate biopsies: valuable tool for risk assessment and prevention trials.
    Nonn L; Vaishnav A; Gallagher L; Gann PH
    Exp Mol Pathol; 2010 Feb; 88(1):45-51. PubMed ID: 19874819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.
    Zhang X; Morrissey C; Sun S; Ketchandji M; Nelson PS; True LD; Vakar-Lopez F; Vessella RL; Plymate SR
    PLoS One; 2011; 6(11):e27970. PubMed ID: 22114732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens.
    Väänänen RM; Lilja H; Cronin A; Kauko L; Rissanen M; Kauko O; Kekki H; Vidbäck S; Nurmi M; Alanen K; Pettersson K
    Clin Biochem; 2013 May; 46(7-8):670-4. PubMed ID: 23391636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis.
    Lin DW; Coleman IM; Hawley S; Huang CY; Dumpit R; Gifford D; Kezele P; Hung H; Knudsen BS; Kristal AR; Nelson PS
    J Clin Oncol; 2006 Aug; 24(23):3763-70. PubMed ID: 16822846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A role for STEAP2 in prostate cancer progression.
    Whiteland H; Spencer-Harty S; Morgan C; Kynaston H; Thomas DH; Bose P; Fenn N; Lewis P; Jenkins S; Doak SH
    Clin Exp Metastasis; 2014 Dec; 31(8):909-20. PubMed ID: 25248617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment.
    Morrissey C; Brown LG; Pitts TE; Vessella RL; Corey E
    Neoplasia; 2010 Feb; 12(2):192-205. PubMed ID: 20126477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.
    Tassidis H; Brokken LJ; Jirström K; Ehrnström R; Pontén F; Ulmert D; Bjartell A; Härkönen P; Wingren AG
    Int J Cancer; 2010 May; 126(10):2296-307. PubMed ID: 19795453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.
    Miyagi Y; Sasaki T; Fujinami K; Sano J; Senga Y; Miura T; Kameda Y; Sakuma Y; Nakamura Y; Harada M; Tsuchiya E
    Mod Pathol; 2010 Nov; 23(11):1492-8. PubMed ID: 20693979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
    Schmittgen TD; Teske S; Vessella RL; True LD; Zakrajsek BA
    Int J Cancer; 2003 Nov; 107(2):323-9. PubMed ID: 12949815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular markers in prostate cancer: the role in preoperative staging.
    Moul JW; Merseburger AS; Srivastava S
    Clin Prostate Cancer; 2002 Jun; 1(1):42-50. PubMed ID: 15046712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells.
    Singh AP; Bafna S; Chaudhary K; Venkatraman G; Smith L; Eudy JD; Johansson SL; Lin MF; Batra SK
    Cancer Lett; 2008 Jan; 259(1):28-38. PubMed ID: 17977648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.